BRISBANE, Calif., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will report fourth quarter and full year 2013 financial results after market closes on Thursday, February 27, 2014. Hyperion will host a webcast and conference call with management to discuss financial results, as well as provide a general corporate update, at 4:30 p.m. ET (1:30 p.m. PT). A live audio webcast of the conference call can be accessed on Hyperion's investor relations website at: http://investors.hyperiontx.com/events.cfm To access the live conference call, dial 877-847-7188 U.S. or 408-427-3787 International and use the conference ID# 69490013. A replay of the call will be available for seven days by accessing Hyperion's investor relations website or by dialing 855-859-2056 U.S. or (404) 537-3406 International and use conference ID# 69490013 beginning approximately one hour after the conference call concludes. About Hyperion Therapeutics Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. The company's first commercial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns worldwide rights to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, which it markets in the U.S. The compound is also marketed internationally through business partners. For more information, please visit www.hyperiontx.com.
CONTACT: Sylvia Wheeler, Investor Relations (650) 794-7834